Last Thursday, the first dose in Canada of a new biologic treatment for psoriasis was injected at Charlton Health. Guselkumab is marketed under the name of Tremfya and is approved by Health Canada for moderate to severe plaque psoriasis. It is given by injection using a pre-filled syringe on day 1 of treatment, followed by an injection on day 28 and a maintenance of every 8 weeks. Guselkumab works by removing an inflammatory cytokine called interleukin 23, which is produced in excess in the skin cells of patients with psoriasis. We are very excited to be offering this new and effective treatment at Charlton Health.